pharmaphorum November 8, 2022
Due to the pandemic, decentralised trial solutions made the shift from an emerging trend to a crucial element of drug development. Ben Hargreaves examines the latest research suggesting that this transition looks set to become a permanent feature of trials in the years to come.
The pharmaceutical industry’s role in developing effective vaccines against COVID-19 was a major benefit to the industry. For those companies involved in the development and manufacture of approved vaccines and treatments, it led to a surge in revenue. As an added bonus, the solutions developed by the industry boosted its reputation in the short-term, and that seems to have been sustained even after the heights of the pandemic have passed. According to a Harris Poll...
Today's Sponsors
Today's Sponsor